We previously developed cancer-specific anti-HER2 mAbs, H2Mab-214/H2CasMab-1 [32] and H2Mab-250/H2CasMab-2 [33], from 278 clones of anti-HER2 mAbs using glioblastoma LN229-expressed HER2 as an antigen. Here, ERBB2 is linked to cancer.